PTNT
Palatin Technologies, Inc.22.82
+8.33+57.5%
Nov 21, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
38.86MP/E (TTM)
-Basic EPS (TTM)
-32.15Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Palatin Technologies posted Q2 FY2026 collaboration revenue of $116K from its Boehringer Ingelheim deal, following $9.0M YTD from milestones and FTE reimbursements—up from zero a year ago. Operating loss hit $7.3M, wider than last year's $2.6M amid higher R&D on MC4R programs and G&A, yielding diluted EPS of -$2.86 on 2.5M shares (anti-dilutive). Cash swelled to $14.5M on $18M equity raise and $1.5M warrant exercises, despite $6.4M operating burn; no capex disclosed for FCF. Equity financings flipped a $4.8M deficit to $11.5M equity. Post-period, $3.8M debt canceled via PL9643 sublicense to Altanispac. FDA funding shortfalls could delay IND reviews.
10-Q
Q1 FY2026 results
Palatin swung to $4.7M net income for Q1 FY2026 ended September 30, 2025, on $8.8M collaboration revenue from its August Boehringer Ingelheim deal—up from zero a year ago—while slashing R&D to $2.5M and SG&A to $1.7M, yielding $4.7M operating income. Cash burned $1.6M operationally but warrant exercises added $0.3M, leaving $1.3M on hand amid $8.2M current liabilities; subsequent BI milestone cash and a November offering eased going concern worries. EPS hit $4.26 diluted on 1.1M shares, matching the math. Deal closed in August 2025, assigning retinal patents for upfront/milestones up to $328M plus royalties. Government shutdowns risk FDA delays.
8-K
Offering closes at $18.2M
Palatin Technologies closed its upsized public offering on November 12, 2025, with underwriters fully exercising the over-allotment option for 280,615 shares and 84,000 pre-funded warrants at $6.50 each, plus Series J and K warrants, yielding $18.2 million gross proceeds. Funds will advance its obesity program and general purposes. Trading resumed on NYSE American. Compliance restored.
8-K
Palatin prices $15.8M offering
Palatin priced a $15.8M public offering of 2.43M shares plus Series J and K warrants at $6.50 each, closing November 12 alongside NYSE American relisting under PTN after equity compliance via prior Boehringer deal and reverse split. Net proceeds fund obesity program development. Warrants hinge on FDA IND acceptance.
10-K
FY2025 results
Palatin Technologies posted a $17.3 million net loss for FY2025 ended June 30, 2025, amid ongoing clinical advancements but no revenue stream post-Vyleesi sale. Q4 saw heavy financing activity—$340K from Series D preferred, $1.1M from May common stock/warrants—bolstering cash for MC4R obesity programs, including positive Phase 2 bremelanotide+tirzepatide data in Q1 CY2025. Warrant exercises added $3.4M in December 2024. No dividends or buybacks; capex not disclosed. Stock delisted to OTCQB May 2025. Going concern warning looms large.
BLRX
BioLineRx Ltd.
3.01-0.17
CORT
Corcept Therapeutics Incorporat
81.12-6.18
CRNX
Crinetics Pharmaceuticals, Inc.
48.61-0.71
LPCN
Lipocine Inc.
3.15+0.00
PALI
Palisade Bio, Inc.
1.72-0.09
PHAT
Phathom Pharmaceuticals, Inc.
15.24+0.55
PLRX
Pliant Therapeutics, Inc.
1.25+0.01
PLRZ
Polyrizon Ltd.
11.19-0.63
PTGX
Protagonist Therapeutics, Inc.
91.54-3.25
PVLA
Palvella Therapeutics, Inc.
96.81+7.83